Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATEN trial of pembrolizumab + paclitaxel in PAM50 non-luminal HR-positive/HER2-negative advanced or metastatic breast cancer after CDK4/6 inhibitor progression
2018-003367-58Phase 2Suspended
- Sponsor
- SOLTI
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and paclitaxel in breast cancer, sponsored by SOLTI. Primary endpoint: Overall response rate. Started Dec 2019; status: suspended.
02
Drugs
pembrolizumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003367-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003367-58.